• Login
Tuesday, March 24, 2026
Geneva Times
  • Home
  • Editorial
  • Switzerland
  • Europe
  • International
  • UN
  • Business
  • Sports
  • More
    • Article
    • Tamil
No Result
View All Result
  • Home
  • Editorial
  • Switzerland
  • Europe
  • International
  • UN
  • Business
  • Sports
  • More
    • Article
    • Tamil
No Result
View All Result
Geneva Times
No Result
View All Result
  • Home
  • Editorial
  • Switzerland
  • Europe
  • International
  • UN
  • Business
  • Sports
  • More
Home Switzerland

Swiss insurers fear cost explosion from weight loss drug

GenevaTimes by GenevaTimes
July 4, 2025
in Switzerland
Reading Time: 4 mins read
0
Swiss insurers fear cost explosion from weight loss drug
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter


Since March 2024, Switzerland’s basic health insurance started reimbursing part of the cost of Wegovy, a weight-loss drug developed by Danish pharmaceutical giant Novo Nordisk. The decision has led to a surge in uptake—and concern among insurers, reported RTS.

© Fernanda Carrasco | Dreamstime.com

Roughly 40,000 people received Wegovy under Switzerland’s mandatory health insurance in 2024, according an association representing health insurers. The drug, which functions primarily as an appetite suppressant, is covered under strict conditions. Yet even with those limitations, reimbursements have climbed sharply. The drug cost insurers CHF 43 million last year and the rise is accelerating.

The Federal Office of Public Health (FOPH) reported that around 250,000 monthly doses were reimbursed in 2024. In just the first three months of 2025, insurers had already spent half the previous year’s total on the drug.

Adrien Kay, a spokesman for the association Prio Swiss said that if 2% of the adult population received Wegovy, the annual cost could reach CHF 300 million. Reimbursement is currently authorised until the end February 2027.

Obesity is classified as a chronic illness in Switzerland. Some 43% of Swiss adults are overweight or obese, with 12% falling into the latter category, according to the 2022 Swiss Health Survey. The public health burden is growing: in 2012, direct and indirect costs associated with obesity were estimated at CHF 8 billion. An updated figure is due in the second half of 2025.

Whether reimbursing Wegovy is ultimately cost-effective remains unclear. Advocates argue it could reduce the prevalence of comorbidities such as diabetes or cardiovascular disease. But critics question whether a lifelong drug treatment is sustainable—or affordable. Also, when the drug is stopped excess weight returns, adding to concerns about the drug’s effectiveness and ongoing cost.

For now, Swiss insurers are authorised to reimburse Wegovy for up to three years. But patients who wish to stay slim after that may be forced to pay out of pocket.

More on this:
RTS article (in French) – Take a 5 minute French test now

For more stories like this on Switzerland follow us on Facebook and Twitter.

Related posts



Read More

Previous Post

Kazakhstan’s Karaganda discloses expansion of industrial production and infrastructure

Next Post

Mets' Jeff McNeil hits go-ahead two-run HR to take lead vs. Yankees

Next Post
Mets' Jeff McNeil hits go-ahead two-run HR to take lead vs. Yankees

Mets' Jeff McNeil hits go-ahead two-run HR to take lead vs. Yankees

ADVERTISEMENT
Facebook Twitter Instagram Youtube LinkedIn

Explore the Geneva Times

  • About us
  • Contact us

Contact us:

editor@thegenevatimes.ch

Visit us

© 2023 -2024 Geneva Times| Desgined & Developed by Immanuel Kolwin

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Editorial
  • Switzerland
  • Europe
  • International
  • UN
  • Business
  • Sports
  • More
    • Article
    • Tamil

© 2023 -2024 Geneva Times| Desgined & Developed by Immanuel Kolwin